Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors.
Gram negative
Gram positive
renal function
sPD-L1
sepsis
viral infections
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
27 11 2023
27 11 2023
Historique:
received:
03
03
2023
accepted:
16
06
2023
medline:
26
10
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
epublish
Résumé
Immune checkpoints play an important role in maintaining the balance of the immune system and in the development of autoimmune diseases. A central checkpoint molecule is the programmed cell death protein 1 (PD-1, CD279) which is typically located on the surface of T cells. Its primary ligand PD-L1 is expressed on antigen presenting cells and on cancer cells. Several variants of PD-L1 exist, among these soluble molecules (sPD-L1) present in serum at low concentrations. sPD-L1 was found elevated in cancer and several other diseases. sPD-L1 in infectious diseases has received relatively little attention so far and is therefore subject of this study. sPD-L1 serum levels were determined in 170 patients with viral infections (influenza, varicella, measles, Dengue fever, SARS-CoV2) or bacterial sepsis by ELISA and compared to the levels obtained in 11 healthy controls. Patients with viral infections and bacterial sepsis generally show significantly higher sPD-L1 serum levels compared to healthy donors, except for varicella samples where results do not reach significance. sPD-L1 is increased in patients with impaired renal function compared to those with normal renal function, and sPD-L1 correlates significantly with serum creatinine. Among sepsis patients with normal renal function, sPD-L1 serum levels are significantly higher in Gram-negative sepsis compared to Gram-positive sepsis. In addition, in sepsis patients with impaired renal function, sPD-L1 correlates positively with ferritin and negatively with transferrin. sPD-L1 serum levels are significantly elevated in patients with sepsis, influenza, mesasles, Dengue fever or SARS-CoV2. Highest levels are detectable in patients with measles and Dengue fever. Also impaired renal function causes an increase in levels of sPD-L1. As a consequence, renal function has to be taken into account in the interpretation of sPD-L1 levels in patients.
Identifiants
pubmed: 37401452
pii: cclm-2023-0232
doi: 10.1515/cclm-2023-0232
doi:
Substances chimiques
B7-H1 Antigen
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2248-2255Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Keir, ME, Freeman, GJ, Sharpe, AH. PD-1 regulates self-reactive CD8 + T cell responses to antigen in lymph nodes and tissues. J Immunol 2007;179:5064–70. https://doi.org/10.4049/jimmunol.179.8.5064 .
doi: 10.4049/jimmunol.179.8.5064
Ajona, D, Ortiz-Espinosa, S, Pio, R. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin Cell Dev Biol 2019;85:153–63. https://doi.org/10.1016/j.semcdb.2017.11.023 .
doi: 10.1016/j.semcdb.2017.11.023
Alsaab, HO, Sau, S, Alzhrani, R, Tatiparti, K, Bhise, K, Kashaw, SK, et al.. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017;8:561. https://doi.org/10.3389/fphar.2017.00561 .
doi: 10.3389/fphar.2017.00561
Khan, M, Zhao, Z, Arooj, S, Fu, Y, Liao, G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol 2020;11:587460. https://doi.org/10.3389/fimmu.2020.587460 .
doi: 10.3389/fimmu.2020.587460
Shen, MJ, Xu, LJ, Yang, L, Tsai, Y, Keng, PC, Chen, Y, et al.. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 2017;8:80506–20. https://doi.org/10.18632/oncotarget.19193 .
doi: 10.18632/oncotarget.19193
Zhang, N, Zeng, Y, Du, W, Zhu, J, Shen, D, Liu, Z, et al.. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol 2016;49:1360–8. https://doi.org/10.3892/ijo.2016.3632 .
doi: 10.3892/ijo.2016.3632
Xu, L, Chen, X, Shen, M, Yang, DR, Fang, L, Weng, G, et al.. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol Oncol 2018;12:269–86. https://doi.org/10.1002/1878-0261.12135 .
doi: 10.1002/1878-0261.12135
Wang, X, Ni, S, Chen, Q, Ma, L, Jiao, Z, Wang, C, et al.. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10: macrophage and bladder cancer. Cell Biol Int 2017;41:177–86. https://doi.org/10.1002/cbin.10716 .
doi: 10.1002/cbin.10716
Xiong, HY, Ma, TT, Wu, BT, Lin, Y, Tu, ZG. IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF-κB signalling. Asian Pac J Cancer Prev 2014;15:5767–72. https://doi.org/10.7314/apjcp.2014.15.14.5767 .
doi: 10.7314/apjcp.2014.15.14.5767
Wang, WB, Yen, ML, Liu, KJ, Hsu, PJ, Lin, MH, Chen, PM, et al.. Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. Stem Cell Rep 2015;5:392–404. https://doi.org/10.1016/j.stemcr.2015.07.013 .
doi: 10.1016/j.stemcr.2015.07.013
Carbotti, G, Barisione, G, Airoldi, I, Mezzanzanica, D, Bagnoli, M, Ferrero, S, et al.. IL-27 induces the expression of Ido and PD-L1 in human cancer cells. Oncotarget 2015;6:43267–80. https://doi.org/10.18632/oncotarget.6530 .
doi: 10.18632/oncotarget.6530
Ng, KW, Attig, J, Young, GR, Ottina, E, Papamichos, SI, Kotsianidis, I, et al.. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. Elife 2019;8:e50256. https://doi.org/10.7554/elife.50256 .
doi: 10.7554/elife.50256
Chen, Y, Wang, Q, Shi, B, Xu, P, Hu, Z, Bai, L, et al.. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 2011;56:231–8. https://doi.org/10.1016/j.cyto.2011.06.004 .
doi: 10.1016/j.cyto.2011.06.004
He, G, Zhang, H, Zhou, J, Wang, B, Chen, Y, Kong, Y, et al.. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141. https://doi.org/10.1186/s13046-015-0256-0 .
doi: 10.1186/s13046-015-0256-0
Ajona, D, Ortiz-Espinosa, S, Moreno, H, Lozano, T, Pajares, MJ, Agorreta, J, et al.. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov 2017;7:694–703. https://doi.org/10.1158/2159-8290.cd-16-1184 .
doi: 10.1158/2159-8290.cd-16-1184
Ding, Y, Sun, C, Li, J, Hu, L, Li, M, Liu, J, et al.. The prognostic significance of soluble programmed death ligand 1 expression in cancers: a systematic review and meta-analysis. Scand J Immunol 2017;86:361–7. https://doi.org/10.1111/sji.12596 .
doi: 10.1111/sji.12596
Ohaegbulam, KC, Assal, A, Lazar-Molnar, E, Yao, Y, Zang, X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21:24–33. https://doi.org/10.1016/j.molmed.2014.10.009 .
doi: 10.1016/j.molmed.2014.10.009
Sunshine, J, Taube, JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32–8. https://doi.org/10.1016/j.coph.2015.05.011 .
doi: 10.1016/j.coph.2015.05.011
Chen, X, Fosco, D, Kline, DE, Meng, L, Nishi, S, Savage, PA, et al.. PD-1 regulates extrathymic regulatory T-cell differentiation: cellular immune response. Eur J Immunol 2014;44:2603–16. https://doi.org/10.1002/eji.201344423 .
doi: 10.1002/eji.201344423
Bailly, C, Thuru, X, Quesnel, B. Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases. Cancers 2021;13:3034. https://doi.org/10.3390/cancers13123034 .
doi: 10.3390/cancers13123034
Sun, S, Chen, Y, Liu, Z, Tian, R, Liu, J, Chen, E, et al.. Serum-soluble PD-L1 may be a potential diagnostic biomarker in sepsis. Scand J Immunol 2021;94:e13049. https://doi.org/10.1111/sji.13049 .
doi: 10.1111/sji.13049
Tannig, P, Peter, AS, Lapuente, D, Klessing, S, Schmidt, A, Damm, D, et al.. Genetic Co-administration of soluble PD-1 ectodomains modifies immune responses against influenza A virus induced by DNA vaccination. Vaccines 2020;8:570. https://doi.org/10.3390/vaccines8040570 .
doi: 10.3390/vaccines8040570
Valero-Pacheco, N, Arriaga-Pizano, L, Ferat-Osorio, E, Mora-Velandia, LM, Pastelin-Palacios, R, Villasís-Keever, MÁ, et al.. PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response. Clin Dev Immunol 2013;2013:1–11. https://doi.org/10.1155/2013/989673 .
doi: 10.1155/2013/989673
Laksono, B, de Vries, R, McQuaid, S, Duprex, W, de Swart, R. Measles virus host invasion and pathogenesis. Viruses 2016;8:210. https://doi.org/10.3390/v8080210 .
doi: 10.3390/v8080210
Liu, M, Zhang, X, Chen, H, Wang, G, Zhang, J, Dong, P, et al.. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients. Scand J Immunol 2017;85:66–72. https://doi.org/10.1111/sji.12509 .
doi: 10.1111/sji.12509
Kushlinskii, NE, Gershtein, ES, Morozov, AA, Goryacheva, IO, Filipenko, ML, Alferov, AA, et al.. Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma. Bull Exp Biol Med 2019;166:353–7. https://doi.org/10.1007/s10517-019-04349-8 .
doi: 10.1007/s10517-019-04349-8
Li, Y, Zhao, R, Cheng, K, Zhang, K, Wang, Y, Zhang, Y, et al.. Bacterial outer membrane vesicles presenting programmed death 1 for improved cancer immunotherapy via immune activation and checkpoint inhibition. ACS Nano 2020;14:16698–711. https://doi.org/10.1021/acsnano.0c03776 .
doi: 10.1021/acsnano.0c03776
Vanaja, SK, Russo, AJ, Behl, B, Banerjee, I, Yankova, M, Deshmukh, SD, et al.. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell 2016;165:1106–19. https://doi.org/10.1016/j.cell.2016.04.015 .
doi: 10.1016/j.cell.2016.04.015
Zhang, G, Meredith, TC, Kahne, D. On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr Opin Microbiol 2013;16:779–85. https://doi.org/10.1016/j.mib.2013.09.007 .
doi: 10.1016/j.mib.2013.09.007
Haschka, D, Hoffmann, A, Weiss, G. Iron in immune cell function and host defense. Semin Cell Dev Biol 2021;115:27–36. https://doi.org/10.1016/j.semcdb.2020.12.005 .
doi: 10.1016/j.semcdb.2020.12.005
Wu, X, Xu, L, Cheng, Q, Nie, L, Zhang, S, Du, Y, et al.. Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: a monocentric cross-sectional study. Respir Med 2020;166:105948. https://doi.org/10.1016/j.rmed.2020.105948 .
doi: 10.1016/j.rmed.2020.105948
Lanser, L, Fuchs, D, Kurz, K, Weiss, G. Physiology and inflammation driven pathophysiology of iron homeostasis-mechanistic insights into anemia of inflammation and its treatment. Nutrients 2021;13:3732. https://doi.org/10.3390/nu13113732 .
doi: 10.3390/nu13113732